Nanoscale Zeolitic Imidazolate Framework (ZIF)-8 in Cancer Theranostics: Current Challenges and Prospects.
Nanoscale Zeolitic Imidazolate Framework (ZIF)-8 in Cancer Theranostics: Current Challenges and Prospects.
复制标题
DOI:
10.3390/cancers14163935
复制
发表时间:
2022-08-15
期刊:
影响因子:
5.2
通讯作者:
Gong, Yan
中科院分区:
文献类型:
--
作者:
Xie, Hongxin;Liu, Xinyu;Huang, Zhengrong;Xu, Liexi;Bai, Rui;He, Fajian;Wang, Mengqin;Han, Linzhi;Bao, Zhirong;Wu, Yuzhou;Xie, Conghua;Gong, Yan
关键词:
The biomedical application of metal–organic frameworks in cancer theranostics has become a research hotspot with rapid progress. As a typical representative, ZIF–8 attracts increasing interest from researchers due to its good performance and potential. In this review, we updated recent discoveries on the ZIF–8–based nanoplatforms for cancer, discussed the problems in current research and the obstacles for clinical translation of ZIF–8, and also proposed an outlook on its future development. Cancer severely threatens human health and has remained the leading cause of disease–related death for decades. With the rapid advancement of nanomedicine, nanoscale metal–organic frameworks are believed to be potentially applied in the treatment and biomedical imaging for various tumors. Zeolite imidazole framework (ZIF)–8 attracts increasing attention due to its high porosity, large specific surface area, and pH–responsiveness. The designs and modifications of ZIF–8 nanoparticles, as well as the strategy of drug loading, demand a multifaceted and comprehensive understanding of nanomaterial features and tumor characteristics. We searched for studies on ZIF–8–based nanoplatforms in tumor theranostics on Web of Science from 2015 to 2022, mainly focused on the research published in the past 3 years, summarized the progress of their applications in tumor imaging and treatment, and discussed the favorable aspects of ZIF–8 nanoparticles for tumor theranostics as well as the future opportunities and potential challenges. As a kind of metal–organic framework material full of potential, ZIF–8 can be expected to be combined with more therapeutic systems in the future and continue to contribute to all aspects of tumor therapy and diagnosis.
登录
查看更多内容
影响因子:
12.4
作者:
Fang, Chao;Cen, Dong;Han, Gaorong
通讯作者:
Han, Gaorong
影响因子:
9.5
作者:
Feng, Jie;Yu, Wenqian;Wang, Fuan
通讯作者:
Wang, Fuan
影响因子:
19
作者:
Dong, Liang;Liu, Yun;Wen, Long-Ping
通讯作者:
Wen, Long-Ping
影响因子:
8.8
作者:
Donato, Cinzia;Kunz, Leo;Aceto, Nicola
通讯作者:
Aceto, Nicola
影响因子:
3.8
作者:
Araújo EF;Loures FV;Bazan SB;Feriotti C;Pina A;Schanoski AS;Costa TA;Calich VL
通讯作者:
Calich VL